Loading…
Equillium, Inc. is projected to rise to $2.82 by 2027, a +28% move from its current price of $2.20. EQ is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $2.11 | $2.20 | $2.29 | +0.02% |
| Aug 5 | $2.08 | $2.20 | $2.33 | +0.05% |
| Aug 6 | $2.05 | $2.20 | $2.36 | +0.07% |
| Aug 7 | $2.03 | $2.20 | $2.39 | +0.10% |
| Aug 8 | $2.01 | $2.20 | $2.42 | +0.13% |
| Aug 9 | $1.99 | $2.20 | $2.44 | +0.15% |
| Aug 10 | $1.98 | $2.20 | $2.46 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.98 | $2.20 | $2.46 | +0.18% |
| Week 2 | $1.89 | $2.21 | $2.58 | +0.35% |
| Week 3 | $1.83 | $2.21 | $2.67 | +0.53% |
| Week 4 | $1.78 | $2.22 | $2.76 | +0.70% |
| Week 5 | $1.74 | $2.22 | $2.83 | +0.88% |
| Week 6 | $1.70 | $2.22 | $2.90 | +1.05% |
| Week 7 | $1.67 | $2.23 | $2.97 | +1.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Equillium, Inc. is a clinical-stage biotechnology company that develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. It was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. (EQ) is currently priced at $2.32 per share with a market capitalization of $146.69M, and it ranks 3835 by market cap.
The stock operates within the Healthcare sector. The thirty-day range runs from $1.72 to $3.12, with the 50-day simple moving average at $2.72 and the 200-day simple moving average at $1.84. Near-term support sits at $2.46 and resistance at $3.20, reflecting a window of opportunity as price action evolves.
The forecast shows a multi-year upside, with the average price rising from $2.32 in 2026 to $35.68 by 2050 and a max of $81.85. This implies meaningful appreciation possible over time, alongside a wide expected price range and high upside, albeit with accompanying volatility. The annualized volatility stands at 90.0% in the data provided.
A major floor 30.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 45.5% above — a clean break opens room to run.
A major ceiling 60.6% above — clearing it would confirm fresh momentum.
Key EQ support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EQ market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.32 | Sell | $2.32 | Sell |
| MA 10 | $2.46 | Sell | $2.43 | Sell |
| MA 20 | $2.63 | Sell | $2.56 | Sell |
| MA 50 | $2.74 | Sell | $2.60 | Sell |
| MA 100 | $2.40 | Sell | $2.39 | Sell |
| MA 200 | $1.86 | Buy | $2.02 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.63 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -139.00 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -16.03 | Sell |
| Bollinger %B (20,2) | 0.06 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.43 | Sell |
| Awesome (5,34) | -0.44 | Sell |
| Ultimate (7,14,28) | 17.03 | Buy |
| Momentum (10) | -0.39 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 2.19 | Buy |
| ADX (14) | 15.73 | Neutral |
| ATR (14) | 0.11 | Info |
Sentiment is BULLISH in the near term. The RSI(14) sits at 40, with the SMA50 at $2.72 and the SMA200 at $1.84, indicating the near-term price is trading above long-run averages but with modest momentum indicators.
Key near-term levels include support at $2.46 and resistance at $3.20. The current 30-day price range is $1.72 to $3.12, highlighting elevated volatility and a broad trading band in which the stock has fluctuated over the past month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.06 | $2.20 | $3.14 | 0% | Neutral | |
| $2.15 | $2.82 | $3.98 | +28% | Bullish | |
| $3.19 | $4.39 | $6.53 | +100% | Bullish | |
| $3.54 | $5.05 | $7.82 | +130% | Bullish | |
| $3.54 | $5.23 | $8.38 | +138% | Bullish | |
| $3.84 | $5.86 | $9.66 | +166% | Bullish | |
| $3.85 | $6.04 | $10.22 | +175% | Bullish | |
| $4.09 | $6.61 | $11.44 | +200% | Bullish | |
| $4.67 | $7.75 | $13.71 | +252% | Bullish | |
| $5.79 | $9.85 | $17.77 | +348% | Bullish | |
| $6.61 | $12.69 | $24.85 | +477% | Bullish | |
| $15.51 | $34.46 | $75.74 | +14.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.06 | $2.20 | $2.84 | +0.00% |
| September 2026 | $1.91 | $2.29 | $2.85 | +4.23% |
| October 2026 | $1.86 | $2.25 | $2.85 | -1.84% |
| November 2026 | $1.94 | $2.37 | $3.03 | +5.32% |
| December 2026 | $1.97 | $2.42 | $3.14 | +2.29% |
Click any year to see its month-by-month EQ forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, EQ could reach as high as $3.14, with a base case around $2.20 and support toward $1.06 — roughly 0% from $2.20. A consolidation phase looks the most probable path here.
Expect EQ to range from $2.15 to $3.98 through 2027. The $2.82 average target implies a +28% move from current prices. That is up +28% on the projected 2026 average. Momentum favours further upside here.
The EQ price prediction for 2028 points to an average of $4.39 (low $3.19, high $6.53) — a potential gain of +100% on today's $2.20. Buyers look set to stay in control over this stretch.
In 2029, EQ is projected to trade between $3.54 and $7.82, averaging $5.05 — a potential gain of +130% from today's $2.20. That is up +15% on the projected 2028 average. Momentum favours further upside here.
Equillium, Inc.'s 2030 outlook centres on $5.23, within a $3.54 to $8.38 range. That is up +4% on the projected 2029 average. That marks a +138% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, EQ could reach as high as $9.66, with a base case around $5.86 and support toward $3.84 — roughly +166% from $2.20. Momentum favours further upside here.
Expect EQ to range from $3.85 to $10.22 through 2032. The $6.04 average target implies a +175% move from current prices. That is up +3% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The EQ price prediction for 2033 points to an average of $6.61 (low $4.09, high $11.44) — a potential gain of +200% on today's $2.20. Momentum favours further upside here.
In 2034, EQ is projected to trade between $4.67 and $13.71, averaging $7.75 — a potential gain of +252% from today's $2.20. That is up +17% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Equillium, Inc.'s 2035 outlook centres on $9.85, within a $5.79 to $17.77 range. That is up +27% on the projected 2034 average. That marks a +348% change versus current levels. Momentum favours further upside here.
By 2040, EQ could reach as high as $24.85, with a base case around $12.69 and support toward $6.61 — roughly +477% from $2.20. Buyers look set to stay in control over this stretch.
Expect EQ to range from $15.51 to $75.74 through 2050. The $34.46 average target implies a +14.7x move from current prices. That is up +171% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in EQ today (≈ 454.545455 EQ) could be worth
$15,662.39
+$14,662.39 (+1466%) by 2050 · US Dollar
Based on the average projected EQ price of $34.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EQwould be worth at today's price.
$1,000 invested in EQ on Jul 31, 2025 (≈ 2,564.102658 EQ) would be worth
$5,641.03
+$4,641.03 (+464.1%) today · 5.64× · US Dollar
Based on a EQ entry price of $0.39 vs. today's $2.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.49 | $883.53 | -11.6% |
| 1 month ago | $3.04 | $723.68 | -27.6% |
| 3 months ago | $2.08 | $1,057.69 | +5.8% |
| 6 months ago | $1.51 | $1,456.95 | +45.7% |
| 1 year ago | $0.39 | $5,641.03 | +464.1% |
| All time (5.0y) ago | $5.79 | $379.97 | -62.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EQ forecast.
Our base-case forecast reaches $4.40 around 2029.
Implied market cap at $4.40: $278.2M
The multi-year forecast shows a bullish trajectory with rising averages and substantial upside potential. For 2027 the average price is $2.96 with a max of $4.24 and an ROI of 27.6; the sentiment is BULLISH. For 2028 the average is $4.76 with a max of $7.23 and an ROI of 105.3.
For 2029 the average is $5.38 with a max of $8.52 and an ROI of 131.8, and for 2030 the average is $5.51 with a max of $9.05 and an ROI of 137.3, with sentiment continuing to be BULLISH.
By 2031 the average rises to $6.25 and by 2032 to $6.26, with further gains through 2033 ($6.81) and 2034 ($8.13), followed by 2035 at $10.29. The longer-horizon forecast shows a substantial uplift: by 2040 the average is $13.14 (max $26.70, ROI 466.6) and by 2050 the average is $35.68 (max $81.85, ROI 1438), with sentiment still BULLISH.
These are estimates and not guarantees, and the forecast acknowledges higher uncertainty given the nature of clinical-stage biotech and market dynamics. The figures reflect the projected path under the provided inputs, including the high volatility implied by the data (annualized volatility at 90%).
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $5.51, a min of $3.63, a max of $9.05, and an ROI of 137.3. The sentiment is BULLISH.
The forecast suggests bullish sentiment from 2027 onward with rising average prices and high ROIs by 2050. These are estimates, not guarantees, and market outcomes can vary.
The current price is $2.32.
The 30-day range is $1.72 to $3.12.
Equillium, Inc. Community Discussion
0Share your Equillium, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.